Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Retained Earnings (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Retained Earnings readings, the most recent being -$448.5 million for Q4 2025.

  • On a quarterly basis, Retained Earnings changed N/A to -$448.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$448.5 million, a N/A change, with the full-year FY2025 number at -$448.5 million, changed N/A from a year prior.
  • Retained Earnings hit -$448.5 million in Q4 2025 for Avalo Therapeutics, down from -$434.8 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$208.5 million in Q1 2021 to a low of -$456.4 million in Q1 2024.
  • Median Retained Earnings over the past 5 years was -$321.7 million (2023), compared with a mean of -$328.2 million.
  • Biggest five-year swings in Retained Earnings: tumbled 53.96% in 2021 and later rose 16.0% in 2025.
  • Avalo Therapeutics' Retained Earnings stood at -$262.2 million in 2021, then decreased by 15.89% to -$303.8 million in 2022, then decreased by 10.31% to -$335.1 million in 2023, then grew by 0.06% to -$334.9 million in 2024, then crashed by 33.92% to -$448.5 million in 2025.
  • The last three reported values for Retained Earnings were -$448.5 million (Q4 2025), -$434.8 million (Q3 2025), and -$404.2 million (Q2 2025) per Business Quant data.